目的 探讨瑞舒伐他汀和阿托伐他汀对冠心病患者的临床疗效及对血清中白介素-35（IL-35）、核因子-κB （NF-κB）水平的影响。方法 选取100例冠心病患者，根据使用药物不同分为两组，对照组（49例）口服阿托伐他汀钙片，观察组（51例）口服瑞舒伐他汀钙片，通过治疗前后的血脂水平，IL-35、NF-κB水平及治疗期间不良反应发生情况，评价不同他汀类药物对冠心病患者的临床疗效差异。结果 治疗前，两组三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）水平相比，无统计学差异；治疗后，两组TG、TC、LDL-C水平均降低，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组LDL-C水平低于对照组，差异有统计学意义（P<0.05），TG、TC水平比较无统计学差异；两组HDL-C水平均升高，同组治疗前后比较差异有统计学意义（P<0.05），但组间比较无统计学差异。治疗前，两组血清IL-35、NF-κB水平相比，无统计学差异；治疗后，两组患者血清IL-35水平均升高，血清NF-κB水平均降低，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组IL-35水平明显高于对照组，NF-κB水平明显低于对照组，差异有统计学意义（P<0.05）。治疗期间，两组不良反应率无统计学差异。结论 瑞舒伐他汀和阿托伐他汀对冠心病均具有较好的调脂作用，瑞舒伐他汀对LDL-C的降低效果更明显，此外，瑞舒伐他汀能更好地控制体内炎症反应，不良反应少，是临床治疗冠心病的理想药物。

Objective To compare the clinical efficacy and serum levels of IL-35 and NF-κB of rosuvastatin and atorvastatin in patients with coronary heart disease. Methods 100 patients with coronary heart disease were selected, they were divided into two groups according to different statins. The control group (49 cases) was given atorvastatin calcium tablets. The observation group (51 cases) was given rosuvastatin calcium tablets. The effect of different statins in treatment of coronary heart disease was evaluated by lipid levels, IL-35, NF-κB level before and after treatment, adverse reaction during treatment. Results Before treatment, The TG, TC, LDL-C, HDL-C levels of two groups had no significant difference. After treatment, the TG, TC, LDL-C levels of two groups were decreased, and the LDL-C level in the observation group was lower than that of the control group (P<0.05). The TG, TC level had no significant differences between two groups. After treatment, the HDL-C levels were increased in two groups. There were no significant differences between groups. Before treatment, there were no statistical significance on serum IL-35, NF-κB level. After treatment, the IL-35 level was increased and NF-κB was decreased in two groups (P<0.05). And the IL-35 level was higher than that of the control group, the NF-κB level was lower than that the control group (P<0.05). During treatment, there was no statistical significance on adverse reaction between two groups. Conclusion Rosuvastatin and Atorvastatin have good lipid-lowering effect on coronary heart disease. Rosuvastatin can reduce the LDL-C obviously. These drugs can control the inflammation reaction, with less adverse reaction. It is the ideal lipid-lowering drug in clinical treatment of coronary heart disease.